Premorbid aspirin use is not associated with lower mortality in older inpatients with SARS-CoV-2 pneumonia

Abstract

To assess the association between aspirin use and in-hospital 30-day mortality, SIPTW-adjusted Kaplan-Meier and Cox proportional hazards regression analyses were performed. Of the 1047 patients with SARS-CoV-2 pneumonia and median age 86 years, 301 (28.7%) were taking aspirin treatment before admission. One hundred forty-seven (34.3%) patients who had taken aspirin died in hospital within 1 month vs 118 patients (30.7%) without aspirin. After SIPTW, aspirin treatment was not significantly associated with lower mortality (adjusted hazard ratio: 1.10 [0.81-1.49], P = .52). Moreover, patients on aspirin had a longer hospital stay and were Abstract Platelet aggregation has been associated with COVID-19 pathogenesis. In older patients hospitalized for SARS-CoV-2 pneumonia, we aimed to investigate the association between aspirin use before admission and the risk of in-hospital all-cause mortality. We performed a retrospective international cohort study in five COVID-19 geriatric units in France and Switzerland. Among 1,357 consecutive hospitalized patients aged 75 or older and testing positive for SARS-CoV-2, we included 1,072 with radiologically confirmed pneumonia. To adjust for confounders, a propensity score for treatment was created, and stabilized inverse probability of treatment weighting

Associations between the use of aspirin or other antiplatelet drugs and all-cause mortality among patients with COVID-19: A meta-analysis

“…Data were abstracted by four authors (WS, HM, ZG, and QC) from 34 studies, ( Abu-Jamous et al, 2020 ; Alamdari et al, 2020 ; Giacomelli et al, 2020 ; Lodigiani et al, 2020 ; Russo et al, 2020 ; Sahai et al, 2020 ; Tremblay et al, 2020 ; Chow et al, 2021a ; Chow et al, 2021b ; Connors et al, 2021 ; Fröhlich et al, 2021 ; Haji Aghajani et al, 2021 ; Ho et al, 2021 ; Kim et al, 2021 ; Liu et al, 2021 ; Meizlish et al, 2021 ; Merzon et al, 2021 ; Mura et al, 2021 ; Osborne et al, 2021 ; Pan et al, 2021 ; Sisinni et al, 2021 ; Son et al, 2021 ; Xiang et al, 2021 ; Yuan et al, 2021 ; Zhao et al, 2021 ; Zhou et al, 2021 ; Al Harthi et al, 2022 ; Santoro et al, 2022a ; Chow et al, 2022 ; Formiga et al, 2022 ; Gogtay et al, 2022 ; RECOVERY Collaborative GroupAbbas et al, 2022 ; REMAP-CAP Writing Committee for the REMAP-CAP InvestigatorsBradbury et al, 2022 ; Sullerot et al, 2022 ), including three randomized controlled trials, ( Connors et al, 2021 ; RECOVERY Collaborative GroupAbbas et al, 2022 ; REMAP-CAP Writing Committee for the REMAP-CAP InvestigatorsBradbury et al, 2022 ), 27 retrospective studies, ( Abu-Jamous et al, 2020 ; Alamdari et al, 2020 ; Lodigiani et al, 2020 ; Russo et al, 2020 ; Sahai et al, 2020 ; Tremblay et al, 2020 ; Chow et al, 2021a ; Chow et al, 2021b ; Fröhlich et al, 2021 ; Haji Aghajani et al, 2021 ; Ho et al, 2021 ; Kim et al, 2021 ; Liu et al, 2021 ; Meizlish et al, 2021 ; Merzon et al, 2021 ; ...…”